Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $140.00.

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Gilead Sciences (GILD – Research Report), ...

Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report ...

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...

Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Twin Momentum Investor model based on the published ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two ...

We recently published a list of 10 Stocks That Analysts Think Will Go Up. In this article, we are going to take a look at ...

Shares have been on the move with the stock up 17.1% over the past month. The stock hit a new 52-week high of $117.39 in the previous session. Gilead Sciences has gained 24.2% since the start of the ...

Fintel reports that on February 18, 2025, Deutsche Bank upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Hold ...

Has Gilead Sciences (GILD) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Gilead Sciences is a member of the Medical sector.